Physician profile
Nancy Lisette O'Connell
NPI 1427149095
$927.84
in general payments reported to CMS, 2019-2025
21 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $262 · 2023: $200 · 2024: $185 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $118.37 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $109.42 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.77 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.26 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $61.42 | 2021-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $56.63 | 2022-2025 | |
| Sanofi Pasteur INC. | $53.71 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $50.85 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $35.38 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.53 | 2022 | |
| Dexcom, INC. | $32.01 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $30.98 | 2022-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Paratek Pharmaceuticals, INC. | $30.29 | 2021 | |
| Pfizer INC. | $29.71 | 2023 | |
| Organon LLC | $24.68 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.91 | 2025 | |
| Ucb, INC. | $18.55 | 2021 | |
| Amgen INC. | $18.27 | 2025 | Otezla, Repatha |
| Sobi, INC | $16.09 | 2023 | |
| Eisai INC. | $16.04 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.97 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy O'Connell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.